RECRUITING Phase 3 ClinicalTrials.gov

TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

Sponsor: Alnylam Pharmaceuticals • ClinicalTrials.gov ID: NCT07052903

Registry updated: 2026-10-20

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Description

The purpose of this study is to: * Evaluate the efficacy of nucresiran compared to placebo on reducing all-cause mortality and cardiovascular (CV) events * Evaluate the efficacy of nucresiran compared to placebo on additional assessments of CV events and/or death * Evaluate the efficacy of nucresiran compared to placebo on patient-reported health status and health-related quality of life

Interventions

Nucresiran (Drug)
Nucresiran 300 mg administered SC q6M
Sterile Normal Saline (0.9% NaCl) (Drug)
Sterile Normal Saline (0.9% NaCl) administered SC once q6M

Eligibility criteria

Inclusion Criteria * Has documented diagnosis of ATTR amyloidosis with cardiomyopathy including those with hereditary ATTR (hATTR) or wild-type ATTR (wATTR) amyloidosis. * Has medical history of heart failure (HF) with at least 1 prior hospitalization for HF or signs and symptoms that require treatment with a diuretic. * Has screening N-terminal prohormone B-type natriuretic peptide (NT-proBNP) \>300 ng/L and \<8500 ng/L; In patients with permanent or persistent atrial fibrillation, screening NT-proBNP \>600 ng/L and \<8500 ng/L. * Patients may be receiving approved TTR stabilizers for ATTR amyloidosis (eg, tafamidis, acoramidis) and may be receiving background therapy for HF at the discretion of the Investigator. Exclusion Criteria * Has New York Heart Association (NYHA) Class IV HF; or NYHA Class III heart failure AND ATTR Amyloidosis Disease Stage 3. * Has a polyneuropathy disability (PND) Score IIIa, IIIb, or IV. * Has an estimated glomerular filtration rate (eGFR) of \<30 mL/min/1.73m\^2 at screening. * Has received prior or currently receiving TTR-lowering therapy

Conditions

Transthyretin Amyloidosis With Cardiomyopathy

Locations

Clinical Trial Site — La Jolla, California, United States
Clinical Trial Site — Laguna Hills, California, United States
Clinical Trial Site — Stanford, California, United States
Clinical Trial Site — Aurora, Colorado, United States
Clinical Trial Site — Norwich, Connecticut, United States
Clinical Trial Site — Washington D.C., District of Columbia, United States
Clinical Trial Site — Brandon, Florida, United States
Clinical Trial Site — Miami, Florida, United States
Clinical Trial Site — Atlanta, Georgia, United States
Clinical Trial Site — Gainesville, Georgia, United States
Clinical Trial Site — Tucker, Georgia, United States
Clinical Trial Site — Chicago, Illinois, United States
Clinical Trial Site — Evanston, Illinois, United States
Clinical Trial Site — Indianapolis, Indiana, United States
Clinical Trial Site — Indianapolis, Indiana, United States
Clinical Trial Site — Kansas City, Kansas, United States
Clinical Trial Site — Baltimore, Maryland, United States
Clinical Trial Site — Boston, Massachusetts, United States
Clinical Trial Site — Boston, Massachusetts, United States
Clinical Trial Site — Detroit, Michigan, United States
Clinical Trial Site — Rochester, Minnesota, United States
Clinical Trial Site — St Louis, Missouri, United States
Clinical Trial Site — Manhasset, New York, United States
Clinical Trial Site — New York, New York, United States
Clinical Trial Site — New York, New York, United States
Clinical Trial Site — New York, New York, United States
Clinical Trial Site — The Bronx, New York, United States
Clinical Trial Site — Charlotte, North Carolina, United States
Clinical Trial Site — Cleveland, Ohio, United States
Clinical Trial Site — Columbus, Ohio, United States
Clinical Trial Site — Portland, Oregon, United States
Clinical Trial Site — Lancaster, Pennsylvania, United States
Clinical Trial Site — Philadelphia, Pennsylvania, United States
Clinical Trial Site — Charleston, South Carolina, United States
Clinical Trial Site — Austin, Texas, United States
Clinical Trial Site — Dallas, Texas, United States
Clinical Trial Site — Houston, Texas, United States
Clinical Trial Site — Plano, Texas, United States
Clinical Trial Site — Salt Lake City, Utah, United States
Clinical Trial Site — Charlottesville, Virginia, United States
Clinical Trial Site — Falls Church, Virginia, United States
Clinical Trial Site — Norfolk, Virginia, United States
Clinical Trial Site — Richmond, Virginia, United States
Clinical Trial Site — Seattle, Washington, United States
Clinical Trial Site — Spokane, Washington, United States
Clinical Trial Site — Buenos Aires, Argentina
Clinical Trial Site — Buenos Aires, Argentina
Clinical Trial Site — Buenos Aires, Argentina
Clinical Trial Site — Buenos Aires, Argentina
Clinical Trial Site — Córdoba, Argentina
Clinical Trial Site — Rosario, Argentina
Clinical Trial Site — Rosario, Argentina
Clinical Trial Site — Rosario, Argentina
Clinical Trial Site — Adelaide, Australia
Clinical Trial Site — Bedford Park, Australia
Clinical Trial Site — Box Hill, Australia
Clinical Trial Site — Chermside, Australia
Clinical Trial Site — Darlinghurst, Australia
Clinical Trial Site — Joondalup, Australia
Clinical Trial Site — Liverpool, Australia
Clinical Trial Site — Westmead, Australia
Clinical Trial Site — Braunau am Inn, Austria
Clinical Trial Site — Graz, Austria
Clinical Trial Site — Vienna, Austria
Clinical Trial Site — Vienna, Austria
Clinical Trial Site — Vienna, Austria
Clinical Trial Site — Vienna, Austria
Clinical Trial Site — Wels, Austria
Clinical Trial Site — Aalst, Belgium
Clinical Trial Site — Bruges, Belgium
Clinical Trial Site — Brussels, Belgium
Clinical Trial Site — Dendermonde, Belgium
Clinical Trial Site — Edegem, Belgium
Clinical Trial Site — Genk, Belgium
Clinical Trial Site — Ghent, Belgium
Clinical Trial Site — Hasselt, Belgium
Clinical Trial Site — Leuven, Belgium
Clinical Trial Site — Liège, Belgium
Clinical Trial Site — Roeselare, Belgium
Clinical Trial Site — Belo Horizonte, Brazil
Clinical Trial Site — Campinas, Brazil
Clinical Trial Site — Porto Alegre, Brazil
Clinical Trial Site — Porto Alegre, Brazil
Clinical Trial Site — Recife, Brazil
Clinical Trial Site — Ribeirão Preto, Brazil
Clinical Trial Site — Ribeirão Preto, Brazil
Clinical Trial Site — Rio de Janeiro, Brazil
Clinical Trial Site — Rio de Janeiro, Brazil
Clinical Trial Site — Salvador, Brazil
Clinical Trial Site — São Paulo, Brazil
Clinical Trial Site — São Paulo, Brazil
Clinical Trial Site — Calgary, Canada
Clinical Trial Site — London, Canada
Clinical Trial Site — Toronto, Canada
Clinical Trial Site — Vancouver, Canada
Clinical Trial Site — Santiago, Chile
Clinical Trial Site — Santiago, Chile
Clinical Trial Site — Binhai, China
Clinical Trial Site — Changsha, China
Clinical Trial Site — Changsha, China
Clinical Trial Site — Chengdu, China
Clinical Trial Site — Dongcheng, China
Clinical Trial Site — Fuzhou, China
Clinical Trial Site — Guangzhou, China
Clinical Trial Site — Haidian, China
Clinical Trial Site — Hangzhou, China
Clinical Trial Site — Hangzhou, China
Clinical Trial Site — Hefei, China
Clinical Trial Site — Hexi District, China
Clinical Trial Site — Jinan, China
Clinical Trial Site — Nanchang, China
Clinical Trial Site — Nangang, China
Clinical Trial Site — Nanjing, China
Clinical Trial Site — Shenzhen Shi, China
Clinical Trial Site — Taiyuan, China
Clinical Trial Site — Wuhan, China
Clinical Trial Site — Xicheng, China
Clinical Trial Site — Yuanjiagang, China
Clinical Trial Site — Brno, Czechia
Clinical Trial Site — Ostrava, Czechia
Clinical Trial Site — Prague, Czechia
Clinical Trial Site — Prague, Czechia
Clinical Trial Site — Aarhus N, Denmark
Clinical Trial Site — København Ø, Denmark
Clinical Trial Site — Odense C, Denmark
Clinical Trial Site — Chambray-lès-Tours, France
Clinical Trial Site — Créteil, France
Clinical Trial Site — Dijon, France
Clinical Trial Site — La Tronche, France
Clinical Trial Site — Marseille, France
Clinical Trial Site — Martinique, France
Clinical Trial Site — Montpellier, France
Clinical Trial Site — Paris, France
Clinical Trial Site — Paris, France
Clinical Trial Site — Pessac, France
Clinical Trial Site — Reims, France
Clinical Trial Site — Rennes, France
Clinical Trial Site — Rouen, France
Clinical Trial Site — Saint-Herblain, France
Clinical Trial Site — Strasbourg, France
Clinical Trial Site — Toulouse, France
Clinical Trial Site — Berlin, Germany
Clinical Trial Site — Cologne, Germany
Clinical Trial Site — Dresden, Germany
Clinical Trial Site — Göttingen, Germany
Clinical Trial Site — Hanover, Germany
Clinical Trial Site — Heidelberg, Germany
Clinical Trial Site — Leipzig, Germany
Clinical Trial Site — Magdeburg, Germany
Clinical Trial Site — Munich, Germany
Clinical Trial Site — Münster, Germany
Clinical Trial Site — Würzburg, Germany
Clinical Trial Site — Athens, Greece
Clinical Trial Site — Athens, Greece
Clinical Trial Site — Heraklion, Greece
Clinical Trial Site — Thessaloniki, Greece
Clinical Trial Site — Hong Kong, Hong Kong
Clinical Trial Site — Balatonfüred, Hungary
Clinical Trial Site — Budapest, Hungary
Clinical Trial Site — Dublin, Ireland
Clinical Trial Site — Dublin, Ireland
Clinical Trial Site — Be’er Ya‘aqov, Israel
Clinical Trial Site — Haifa, Israel
Clinical Trial Site — Jerusalem, Israel
Clinical Trial Site — Petah Tikva, Israel
Clinical Trial Site — Ancona, Italy
Clinical Trial Site — Bologna, Italy
Clinical Trial Site — Brescia, Italy
Clinical Trial Site — Florence, Italy
Clinical Trial Site — Forlì, Italy
Clinical Trial Site — Lecce, Italy
Clinical Trial Site — Milan, Italy
Clinical Trial Site — Naples, Italy
Clinical Trial Site — Padova, Italy
Clinical Trial Site — Pavia, Italy
Clinical Trial Site — Pisa, Italy
Clinical Trial Site — Rimini, Italy
Clinical Trial Site — Roma, Italy
Clinical Trial Site — Rome, Italy
Clinical Trial Site — Torino, Italy
Clinical Trial Site — Bunkyō City, Japan
Clinical Trial Site — Fukuoka, Japan
Clinical Trial Site — Fukuoka, Japan
Clinical Trial Site — Kagawa, Japan
Clinical Trial Site — Kashihara, Japan
Clinical Trial Site — Kobe, Japan
Clinical Trial Site — Kumamoto, Japan
Clinical Trial Site — Kurume, Japan
Clinical Trial Site — Matsumoto-shi, Japan
Clinical Trial Site — Nagoya, Japan
Clinical Trial Site — Nankoku, Japan
Clinical Trial Site — Niigata, Japan
Clinical Trial Site — Okayama, Japan
Clinical Trial Site — Sapporo, Japan
Clinical Trial Site — Sapporo, Japan
Clinical Trial Site — Sendai, Japan
Clinical Trial Site — Suita, Japan
Clinical Trial Site — Tokyo, Japan
Clinical Trial Site — Kajang, Malaysia
Clinical Trial Site — Kuala Lumpur, Malaysia
Clinical Trial Site — Tlalpan, Mexico
Clinical Trial Site — Eindhoven, Netherlands
Clinical Trial Site — Groningen, Netherlands
Clinical Trial Site — Maastricht, Netherlands
Clinical Trial Site — Rotterdam, Netherlands
Clinical Trial Site — Utrecht, Netherlands
Clinical Trial Site — Auckland, New Zealand
Clinical Trial Site — Christchurch, New Zealand
Clinical Trial Site — Hamilton, New Zealand
Clinical Trial Site — Ålesund, Norway
Clinical Trial Site — Lørenskog, Norway
Clinical Trial Site — Lodz, Poland
Clinical Trial Site — Carnaxide, Portugal
Clinical Trial Site — Creixomil, Portugal
Clinical Trial Site — Leiria, Portugal
Clinical Trial Site — Lisbon, Portugal
Clinical Trial Site — Lisbon, Portugal
Clinical Trial Site — Vila Real, Portugal
Clinical Trial Site — Viseu, Portugal
Clinical Trial Site — Bucharest, Romania
Clinical Trial Site — Cluj-Napoca, Romania
Clinical Trial Site — Košice, Slovakia
Clinical Trial Site — Incheon, South Korea
Clinical Trial Site — Seoul, South Korea
Clinical Trial Site — Seoul, South Korea
Clinical Trial Site — Seoul, South Korea
Clinical Trial Site — Seoul, South Korea
Clinical Trial Site — A Coruña, Spain
Clinical Trial Site — Barcelona, Spain
Clinical Trial Site — Barcelona, Spain
Clinical Trial Site — Bilbao, Spain
Clinical Trial Site — El Palmar, Spain
Clinical Trial Site — Huelva, Spain
Clinical Trial Site — Jaén, Spain
Clinical Trial Site — L'Hospitalet de Llobregat, Spain
Clinical Trial Site — Lleida, Spain
Clinical Trial Site — Madrid, Spain
Clinical Trial Site — Madrid, Spain
Clinical Trial Site — Palma de Mallorca, Spain
Clinical Trial Site — Pamplona, Spain
Clinical Trial Site — Salamanca, Spain
Clinical Trial Site — Santiago de Compostela, Spain
Clinical Trial Site — Valencia, Spain
Clinical Trial Site — Valencia, Spain
Clinical Trial Site — Vigo, Spain
Clinical Trial Site — Gothenburg, Sweden
Clinical Trial Site — Lund, Sweden
Clinical Trial Site — Solna, Sweden
Clinical Trial Site — Basel, Switzerland
Clinical Trial Site — Bern, Switzerland
Clinical Trial Site — Geneva, Switzerland
Clinical Trial Site — Lucerne, Switzerland
Clinical Trial Site — Sankt Gallen, Switzerland
Clinical Trial Site — New Taipei City, Taiwan
Clinical Trial Site — Taichung, Taiwan
Clinical Trial Site — Taipei, Taiwan
Clinical Trial Site — Taipei, Taiwan
Clinical Trial Site — Ankara, Turkey (Türkiye)
Clinical Trial Site — Antalya, Turkey (Türkiye)
Clinical Trial Site — Istanbul, Turkey (Türkiye)
Clinical Trial Site — Bellshill, United Kingdom
Clinical Trial Site — Birmingham, United Kingdom
Clinical Trial Site — Cardiff, United Kingdom
Clinical Trial Site — London, United Kingdom
Clinical Trial Site — London, United Kingdom
Clinical Trial Site — Manchester, United Kingdom

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record

Accelerate Your Clinical Trial Recruitment